<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449147</url>
  </required_header>
  <id_info>
    <org_study_id>7264-030</org_study_id>
    <secondary_id>MK-7264-030</secondary_id>
    <secondary_id>2017-003559-49</secondary_id>
    <nct_id>NCT03449147</nct_id>
  </id_info>
  <brief_title>A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in&#xD;
      reducing cough frequency as measured over a 24-hour period, and to determine the safety and&#xD;
      tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is&#xD;
      superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have a main 24-week treatment period and a 28-week extension period of&#xD;
      treatment (total treatment period of 52 weeks). Participants at selected sites and countries&#xD;
      who complete the main and extension study periods may consent to participate in an&#xD;
      observational, 12-week, Off-treatment Durability Study Period. Any assessments conducted in&#xD;
      the observational period will be exploratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups: gefapixant 45 mg twice daily (BID), gefapixant 15 mg BID, or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A longitudinal analysis of covariance (ANCOVA) model was applied to log-transformed cough data to determine geometric mean (GM) 24-hour coughs per hour at baseline and week 24. The GMR (Week 24 GM 24-hour coughs per hour divided by Baseline GM 24-hour coughs per hour) is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up</measure>
    <time_frame>Up to 54 Weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued a Study Drug Due to an AE</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Awake coughs per hour was defined as the average hourly cough frequency while the participant is awake, based on a 24-hour interval of sound recordings using a digital recording device (cough monitor). ANCOVA model was applied to log-transformed cough data to determine GM of awake coughs per hour at baseline and week 24. The GMR (Week 24 GM awake coughs per hour divided by Baseline GM awake coughs per hour) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The 19-item LCQ assessed the impact of chronic cough in three health-related quality of life (HRQoL) domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21. Higher scores indicate better HRQoL. A clinically meaningful improvement from baseline in HRQoL was defined as ≥1.3-point increase in the LCQ total score at Week 24. The percentage of participants (logistic regression model-based) with a ≥1.3-point increase in the LCQ total score at Week 24 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A clinically meaningful improvement from baseline is defined as a ≤-30% change (≥30% reduction) in 24-hour coughs per hour at week 24. The percentage of participants (logistic regression model-based) with a ≤ -30% change from baseline in 24-hour coughs per hour at Week 24 (≥30% reduction from baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≤-1.3 Point Change From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-1.3 point change from baseline in CSD at Week 24 (or ≥1.3 point reduction from baseline) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≤-2.7 Point Change From Baseline of Mean Weekly CSD Total Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-2.7 point change from baseline in CSD at Week 24 (or ≥2.7 point reduction from baseline) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≤-30 Millimeter (mm) Change From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 (&quot;No Cough&quot;) to 100 (&quot;Extremely Severe Cough&quot;). Mean weekly VAS score was defined as the average of the VAS scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-30 mm change from baseline in cough severity VAS score at Week 24 is reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1317</enrollment>
  <condition>Chronic Cough</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefapixant 15 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefapixant 45 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet administered orally BID</description>
    <arm_group_label>Gefapixant 15 mg BID</arm_group_label>
    <arm_group_label>Gefapixant 45 mg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant 15 mg BID</intervention_name>
    <description>Gefapixant 15 mg tablet administered orally BID</description>
    <arm_group_label>Gefapixant 15 mg BID</arm_group_label>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant 45 mg BID</intervention_name>
    <description>Gefapixant 45 mg tablet administered orally BID</description>
    <arm_group_label>Gefapixant 45 mg BID</arm_group_label>
    <other_name>MK-7264</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chest radiograph or computed tomography scan of the thorax (within 5 years of&#xD;
             Screening/Visit 1 and after the onset of chronic cough) not demonstrating any&#xD;
             abnormality considered to be significantly contributing to the chronic cough or any&#xD;
             other clinically significant lung disease in the opinion of the principal investigator&#xD;
             or the sub-investigator&#xD;
&#xD;
          -  Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough&#xD;
             or unexplained chronic cough&#xD;
&#xD;
          -  Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or&#xD;
             agrees to follow contraceptive guidance&#xD;
&#xD;
          -  Provides written informed consent and is willing and able to comply with the study&#xD;
             protocol (including use of the digital cough recording device and completion of study&#xD;
             questionnaires)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a current smoker or has given up smoking within 12 months of Screening, or is a&#xD;
             former smoker with greater than 20 pack-years&#xD;
&#xD;
          -  Has a history of respiratory tract infection or recent clinically significant change&#xD;
             in pulmonary status&#xD;
&#xD;
          -  Has a history of chronic bronchitis&#xD;
&#xD;
          -  Is currently taking an angiotensin converting enzyme inhibitor (ACEI), or has used an&#xD;
             ACEI within 3 months of Screening&#xD;
&#xD;
          -  Has an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m^2 at Screening OR&#xD;
             an eGFR ≥30 mL/min/1.73 m^2 and &lt;50 mL/min/1.73 m^2 at Screening with unstable renal&#xD;
             function&#xD;
&#xD;
          -  Has a history of malignancy ≤5 years&#xD;
&#xD;
          -  Is a user of recreational or illicit drugs or has had a recent history of drug or&#xD;
             alcohol abuse or dependence&#xD;
&#xD;
          -  Has a history of anaphylaxis or cutaneous adverse drug reaction (with or without&#xD;
             systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs&#xD;
&#xD;
          -  Has a known allergy/sensitivity or contraindication to gefapixant&#xD;
&#xD;
          -  Has donated or lost ≥1 unit of blood within 8 weeks prior to the first dose of&#xD;
             gefapixant&#xD;
&#xD;
          -  Has previously received gefapixant&#xD;
&#xD;
          -  Currently participating in or has participated in an interventional clinical study&#xD;
             within 30 days of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Medical Group ( Site 0022)</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA ( Site 0063)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0088)</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of SCV Research Center ( Site 0064)</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group Llc ( Site 0075)</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy &amp; Asthma Clinic PA ( Site 0029)</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center ( Site 0103)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network LLC ( Site 0093)</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abraham Research, PLLC ( Site 0107)</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul A. Shapero, MD ( Site 0104)</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Allergy Asthma and Research Center LLC ( Site 0019)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan, PLC ( Site 0034)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center ( Site 0108)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester ( Site 0006)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center ( Site 0041)</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lung Research Center ( Site 0072)</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri ENT &amp; Allergy Center ( Site 0066)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Creighton University Medical Center ( Site 0024)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0050)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center LLC ( Site 0012)</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials ( Site 0039)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center ( Site 0098)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC ( Site 0058)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc. ( Site 0082)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC ( Site 0099)</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center ( Site 0026)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAPRI Clinical Research Institute ( Site 0001)</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung &amp; Critical Care, PA ( Site 0045)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergic Disease and Asthma Center ( Site 0043)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill ( Site 0079)</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC. ( Site 0080)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma &amp; Allergy ( Site 0076)</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marycliff Clinical Research ( Site 0062)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Health System ( Site 0018)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network ( Site 0201)</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 0206)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital [Adelaide, Australia] ( Site 0214)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trialswest ( Site 0208)</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group ( Site 0510)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recherche GCP Research ( Site 0500)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q &amp; T Research Sherbrooke Inc. ( Site 0512)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Pneumologie et du Sommeil de Lanaudiere- CPSL ( Site 0516)</name>
      <address>
        <city>St-Charles-Borromee</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC Mauricie Inc. ( Site 0503)</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Victoriaville Inc. ( Site 0514)</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Quebec Inc ( Site 0515)</name>
      <address>
        <city>Quebec</city>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Specialisee en Allergie de la Capitale - CSAC ( Site 0504)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University ( Site 5017)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University ( Site 5000)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Autonomous Region Hospital ( Site 5018)</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University ( Site 5012)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ShengJing Hospital of China Medical University ( Site 5024)</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital ( Site 5010)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University ( Site 5014)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital ( Site 5005)</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro de Investigacion Clinica CIC ( Site 0603)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe ( Site 0600)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0602)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neumo Investigaciones SAS ( Site 0622)</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110311</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especializado en Enfermedades Pulmonares. ( Site 0620)</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>111831</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0618)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 0619)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPlus Medicina Prepagada S.A. ( Site 0612)</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Neumologico del Oriente S.A. ( Site 0649)</name>
      <address>
        <city>Bucaramanga</city>
        <zip>681004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Prestadora de Servicios de Salud Universidad Antioquia ( Site 0621)</name>
      <address>
        <city>Medellin</city>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. I. Cierna Peterova s.r.o. ( Site 0707)</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrial s.r.o ( Site 0702)</name>
      <address>
        <city>Jindrichuv Hradec III</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace Pneumologie a diagnostiky Plicnich funkci ( Site 0705)</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 17</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PNEUMO-NB s.r.o. ( Site 0710)</name>
      <address>
        <city>Novy Bor</city>
        <zip>473 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Tabor a.s. ( Site 0703)</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital ( Site 0803)</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital ( Site 0804)</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aerztezentrum Axel Springer Passage ( Site 1009)</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atemwegszentrum Neukoeln ( Site 1003)</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Zentrum ( Site 1005)</name>
      <address>
        <city>Frankfurt</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologicum im Suedstadtforum ( Site 1004)</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologenzentrum ( Site 1006)</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH ( Site 1011)</name>
      <address>
        <city>Neu-Isenburg</city>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PneumoConsult Ulm ( Site 1008)</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinipharm ( Site 2902)</name>
      <address>
        <city>Guatemala</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celan SA ( Site 2900)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado Dr. Jeremias Guerra ( Site 2909)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica Especializada en Neumologia ( Site 2901)</name>
      <address>
        <city>Guatemala</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Privada Dr. Jose Francisco Flores Lopez ( Site 2903)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Kenessey Albert Korhaz-Rendelointezet ( Site 1200)</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft. ( Site 1208)</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erzsebet Gondozohaz ( Site 1207)</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft. ( Site 1210)</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumniczer Sandor Korhaz es Rendelointezet ( Site 1212)</name>
      <address>
        <city>Kapuvar</city>
        <zip>9330</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary KFT ( Site 1205)</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Da Vinci Private Clinic - Da Vinci Maganklinika ( Site 1201)</name>
      <address>
        <city>Pecs</city>
        <zip>7626</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puspokladanyi Egeszsegugyi Szolgaltato Nonprofit Kft ( Site 1203)</name>
      <address>
        <city>Puspokladany</city>
        <zip>4150</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center ( Site 1300)</name>
      <address>
        <city>Rehovot</city>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi ( Site 1400)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah ( Site 1607)</name>
      <address>
        <city>Alor Star</city>
        <state>Kedah</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Taiping ( Site 1600)</name>
      <address>
        <city>Taiping</city>
        <state>Perak</state>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang. ( Site 1606)</name>
      <address>
        <city>George town</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Teknologi MARA ( Site 1602)</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Perubatan Respiratori ( Site 1605)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>53000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 1601)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Waitemata ( Site 0230)</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials ( Site 0232)</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials ( Site 0233)</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research Ltd. ( Site 0228)</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ricardo Palma ( Site 1802)</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Adolfo Guevara Velasco ( Site 1808)</name>
      <address>
        <city>Cusco</city>
        <zip>08000</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional ( Site 1801)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociacion Civil por la Salud ( Site 1805)</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia [Lima, Peru] ( Site 1806)</name>
      <address>
        <city>Lima</city>
        <zip>15102</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ CENTRUM ALERGOLOGII ( Site 1909)</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice ( Site 1917)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Silmedic Sp z o o ( Site 1920)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medycyny Oddechowej Mroz Spolka Jawna ( Site 1918)</name>
      <address>
        <city>Białystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLIMED ( Site 1902)</name>
      <address>
        <city>Bychawa</city>
        <zip>23-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyncentrum Clinic Sp. z o.o. ( Site 1908)</name>
      <address>
        <city>Katowice</city>
        <zip>40-851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny osrodek .All-Med. Grazyna Pulka ( Site 1919)</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Nowoczesnych Terapii Dobry Lekarz ( Site 1924)</name>
      <address>
        <city>Krakow</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Norberta Barlickiego nr 1 ( Site 1921)</name>
      <address>
        <city>Lodz</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostrowieckie Centrum Medyczne ( Site 1915)</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed ( Site 1912)</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne ( Site 1913)</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa ( Site 1911)</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Lucyna Andrzej Dymek - Zawadzkie ( Site 1923)</name>
      <address>
        <city>Zawadzkie</city>
        <zip>47-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatros International ( Site 2130)</name>
      <address>
        <city>Brandwag</city>
        <state>Bloemfontein</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Place Medical Centre ( Site 2129)</name>
      <address>
        <city>Morningside</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jongaie Research ( Site 2131)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr N K Gounden Mediclinic ( Site 2134)</name>
      <address>
        <city>Shallcross</city>
        <state>Kwazulu Natal</state>
        <zip>4093</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs Lalloo &amp; Ambaram ( Site 2132)</name>
      <address>
        <city>Umhlanga Ridge</city>
        <state>Kwazulu Natal</state>
        <zip>4319</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Engelbrecht Research ( Site 2128)</name>
      <address>
        <city>Centurion</city>
        <state>Tswane</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCT Lung Institute - Bateman ( Site 2126)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Tip Fakultesi ( Site 2621)</name>
      <address>
        <city>Bursa</city>
        <state>Gorukle</state>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 2612)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2602)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi ( Site 2619)</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi Gogus Hastalıklari ABD ( Site 2610)</name>
      <address>
        <city>Istambul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSK Sureyyapasa Gogus Hastaliklari Hastanesi ( Site 2608)</name>
      <address>
        <city>Istambul</city>
        <zip>34844</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi ( Site 2603)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBU Dr. Suat Seren Gogus Hast. ve Cer. Egitim ve Arastirma Hast. ( Site 2604)</name>
      <address>
        <city>Izmir</city>
        <zip>35110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University Faculty of Medicine ( Site 2614)</name>
      <address>
        <city>Manisa</city>
        <zip>45030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv City hospital N2 ( Site 2801)</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CE Chernivtsi state city clinical hospital 3 ( Site 2806)</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kherson City Clinical Hospital n.a. Y.Y. Karabelesh ( Site 2812)</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Clinic Blagomed LLC ( Site 2807)</name>
      <address>
        <city>Kiev</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Tuberculosis Hospital No. 1 ( Site 2814)</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Association Medbud of the PJSC Kyivmiskbud ( Site 2803)</name>
      <address>
        <city>Kyiv</city>
        <zip>03037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE Road Clinical Hospital 2 of Kyiv station ( Site 2809)</name>
      <address>
        <city>KYiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Otolaryngology n. a. Prof. A. I. Kolomiychenko ( Site 2833)</name>
      <address>
        <city>Kyiv</city>
        <zip>03067</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2804)</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2830)</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital ( Site 2829)</name>
      <address>
        <city>Lutsk</city>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava City Clinical Hospital 1 ( Site 2808)</name>
      <address>
        <city>Poltava</city>
        <zip>36039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital n.a. M.I. Pyrogov ( Site 2819)</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Zaporizhzhia City Multispecialty Clinical Hospital 9 ( Site 2811)</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Central City Hospital #1 ( Site 2828)</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull &amp; East Yorkshire NHS Trust. Castle Hill Hospital ( Site 2704)</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Centre Ltd ( Site 2719)</name>
      <address>
        <city>Birmingham</city>
        <state>Edgbaston</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova East London Dedicated Research Centre ( Site 2715)</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <zip>RM1 3PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova South London Dedicated Research Centre ( Site 2714)</name>
      <address>
        <city>Sidcup</city>
        <state>Kent</state>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova North London Dedicated Research Centre ( Site 2716)</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova Lakeside Dedicated Research Centre ( Site 2710)</name>
      <address>
        <city>Corby</city>
        <state>Northamptonshire</state>
        <zip>NN17 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinova Warwickshire Dedicated Research Centre ( Site 2717)</name>
      <address>
        <city>Kenilworth</city>
        <state>Warwickshire</state>
        <zip>CV8 1JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital ( Site 2705)</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Centre ( Site 2721)</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Merseyside Clinical Research Centre ( Site 2720)</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 OLG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Phillip Hospital ( Site 2722)</name>
      <address>
        <city>Llanelli</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1Kings College Hospital ( Site 2702)</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Manchester Clinical Research Centre ( Site 2718)</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital ( Site 2700)</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital ( Site 2707)</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothwell Medical Centre ( Site 2712)</name>
      <address>
        <city>Rothwell</city>
        <zip>NN14 6JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taunton and Somerset Hospital ( Site 2723)</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Walk Surgery ( Site 2711)</name>
      <address>
        <city>Yate</city>
        <zip>BS37 4AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <results_first_submitted>August 9, 2021</results_first_submitted>
  <results_first_submitted_qc>August 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03449147/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1317 participants were randomized to the 52-week treatment period, and 1314 participants received at least 1 dose of study intervention. After the main study, 122 participants continued in an optional Off-Treatment observational study period (no treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="P2">
          <title>Gefapixant 15 mg BID</title>
          <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="P3">
          <title>Gefapixant 45 mg BID</title>
          <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>52-week Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="442"/>
                <participants group_id="P3" count="439"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="368"/>
                <participants group_id="P3" count="355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-Week Off-Treatment Durability Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48">Not all participants continued in the optional Off-Treatment Period.</participants>
                <participants group_id="P2" count="37">Not all participants continued in the optional Off-Treatment Period.</participants>
                <participants group_id="P3" count="37">Not all participants continued in the optional Off-Treatment Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="B2">
          <title>Gefapixant 15 mg BID</title>
          <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="B3">
          <title>Gefapixant 45 mg BID</title>
          <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="436"/>
            <count group_id="B2" value="442"/>
            <count group_id="B3" value="439"/>
            <count group_id="B4" value="1317"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="436"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="439"/>
                    <count group_id="B4" value="1317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="12.5"/>
                    <measurement group_id="B2" value="58.4" spread="11.3"/>
                    <measurement group_id="B3" value="57.8" spread="12.4"/>
                    <measurement group_id="B4" value="58.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="436"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="439"/>
                    <count group_id="B4" value="1317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="329"/>
                    <measurement group_id="B4" value="986"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="436"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="439"/>
                    <count group_id="B4" value="1317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="344"/>
                    <measurement group_id="B4" value="1039"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="436"/>
                    <count group_id="B2" value="442"/>
                    <count group_id="B3" value="439"/>
                    <count group_id="B4" value="1317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="346"/>
                    <measurement group_id="B4" value="1060"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline 24-Hour Coughs Per Hour</title>
          <description>24-hour coughs per hour is defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor).</description>
          <population>All participants with 24-hour coughs per hour data available at baseline</population>
          <units>Coughs/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="432"/>
                    <count group_id="B2" value="431"/>
                    <count group_id="B3" value="434"/>
                    <count group_id="B4" value="1297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.45" spread="24.44"/>
                    <measurement group_id="B2" value="26.82" spread="21.25"/>
                    <measurement group_id="B3" value="26.84" spread="27.04"/>
                    <measurement group_id="B4" value="27.04" spread="24.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline</title>
        <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A longitudinal analysis of covariance (ANCOVA) model was applied to log-transformed cough data to determine geometric mean (GM) 24-hour coughs per hour at baseline and week 24. The GMR (Week 24 GM 24-hour coughs per hour divided by Baseline GM 24-hour coughs per hour) is reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who took at least 1 dose of study intervention, had available 24-hour cough data at baseline and at least one available post-baseline measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg BID</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline</title>
          <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A longitudinal analysis of covariance (ANCOVA) model was applied to log-transformed cough data to determine geometric mean (GM) 24-hour coughs per hour at baseline and week 24. The GMR (Week 24 GM 24-hour coughs per hour divided by Baseline GM 24-hour coughs per hour) is reported.</description>
          <population>All randomized participants who took at least 1 dose of study intervention, had available 24-hour cough data at baseline and at least one available post-baseline measurement during the treatment period.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.39" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.43" lower_limit="0.38" upper_limit="0.47"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.33" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated relative reduction (ERR) relative to Placebo (i.e. estimated percent change difference) was calculated by 100 (e**DIFF -1), where e = exponent of difference; and DIFF= treatment difference in change from baseline at Week 24 based on log transformed data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.875</p_value>
            <p_value_desc>Comparison based on a longitudinal ANCOVA model that included treatment, visit, treatment-by-visit interaction, gender, region, log-transformed baseline value, and log-transformed baseline value-by-visit as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Estimated Relative Reduction (%)</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.27</ci_lower_limit>
            <ci_upper_limit>14.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ERR relative to Placebo (i.e. estimated percent change difference) was calculated by 100 (e**DIFF -1), where e = exponent of difference; and DIFF= treatment difference in change from baseline at Week 24 based on log transformed data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>Comparison based on a longitudinal ANCOVA model that included treatment, visit, treatment-by-visit interaction, gender, region, log-transformed baseline value, and log-transformed baseline value-by-visit as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Estimated Relative Reduction (%)</param_type>
            <param_value>-14.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.07</ci_lower_limit>
            <ci_upper_limit>-1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to 54 Weeks</time_frame>
        <population>All randomized participants who received at least one dose of study intervention during the 52-week treatment period. Per protocol, participants in the optional off-treatment observational period were not included. 3 participants randomized to placebo group who took 1 or more incorrect dose(s) of study drug were counted in the higher dose group of gefapixant received: 2 participants were analyzed in the gefapixant 15 mg group and 1 was analyzed in the gefapixant 45 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg BID</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All randomized participants who received at least one dose of study intervention during the 52-week treatment period. Per protocol, participants in the optional off-treatment observational period were not included. 3 participants randomized to placebo group who took 1 or more incorrect dose(s) of study drug were counted in the higher dose group of gefapixant received: 2 participants were analyzed in the gefapixant 15 mg group and 1 was analyzed in the gefapixant 45 mg group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="442"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                    <measurement group_id="O2" value="373"/>
                    <measurement group_id="O3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued a Study Drug Due to an AE</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study intervention during the 52-week treatment period. Per protocol, participants in the optional off-treatment observational period were not included. 3 participants randomized to placebo group who took 1 or more incorrect dose(s) of study drug were counted in the higher dose group of gefapixant received: 2 participants were analyzed in the gefapixant 15 mg group and 1 was analyzed in the gefapixant 45 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg BID</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued a Study Drug Due to an AE</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
          <population>All randomized participants who received at least one dose of study intervention during the 52-week treatment period. Per protocol, participants in the optional off-treatment observational period were not included. 3 participants randomized to placebo group who took 1 or more incorrect dose(s) of study drug were counted in the higher dose group of gefapixant received: 2 participants were analyzed in the gefapixant 15 mg group and 1 was analyzed in the gefapixant 45 mg group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="442"/>
                <count group_id="O3" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline</title>
        <description>Awake coughs per hour was defined as the average hourly cough frequency while the participant is awake, based on a 24-hour interval of sound recordings using a digital recording device (cough monitor). ANCOVA model was applied to log-transformed cough data to determine GM of awake coughs per hour at baseline and week 24. The GMR (Week 24 GM awake coughs per hour divided by Baseline GM awake coughs per hour) is reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who took at least 1 dose of study intervention, had available awake 24-hour cough data at baseline and at least one available post-baseline measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg BID</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Model-Based GMR of Awake Coughs Per Hour at Week 24/Baseline</title>
          <description>Awake coughs per hour was defined as the average hourly cough frequency while the participant is awake, based on a 24-hour interval of sound recordings using a digital recording device (cough monitor). ANCOVA model was applied to log-transformed cough data to determine GM of awake coughs per hour at baseline and week 24. The GMR (Week 24 GM awake coughs per hour divided by Baseline GM awake coughs per hour) is reported.</description>
          <population>All randomized participants who took at least 1 dose of study intervention, had available awake 24-hour cough data at baseline and at least one available post-baseline measurement during the treatment period.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.38" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.41" lower_limit="0.37" upper_limit="0.46"/>
                    <measurement group_id="O3" value="0.36" lower_limit="0.32" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated relative reduction (ERR) relative to Placebo (i.e. estimated percent change difference) was calculated by 100 (e**DIFF -1), where e = exponent of difference; and DIFF= treatment difference in change from baseline at Week 24 based on log transformed data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>Comparison based on a longitudinal ANCOVA model that included treatment, visit, treatment-by-visit interaction, gender, region, log-transformed baseline value, and log-transformed baseline value-by-visit as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Estimated Relative Reduction (%)</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.14</ci_lower_limit>
            <ci_upper_limit>12.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ERR relative to Placebo (i.e. estimated percent change difference) was calculated by 100 (e**DIFF -1), where e = exponent of difference; and DIFF= treatment difference in change from baseline at Week 24 based on log transformed data.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>Comparison based on a longitudinal ANCOVA model that included treatment, visit, treatment-by-visit interaction, gender, region, log-transformed baseline value, and log-transformed baseline value-by-visit as covariates.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Estimated Relative Reduction (%)</param_type>
            <param_value>-15.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.27</ci_lower_limit>
            <ci_upper_limit>-2.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24</title>
        <description>The 19-item LCQ assessed the impact of chronic cough in three health-related quality of life (HRQoL) domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21. Higher scores indicate better HRQoL. A clinically meaningful improvement from baseline in HRQoL was defined as ≥1.3-point increase in the LCQ total score at Week 24. The percentage of participants (logistic regression model-based) with a ≥1.3-point increase in the LCQ total score at Week 24 is presented.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had taken at least 1 dose of study intervention, had available LCQ data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥1.3 Point Change From Baseline in the Leicester Questionnaire (LCQ) Total Score at Week 24</title>
          <description>The 19-item LCQ assessed the impact of chronic cough in three health-related quality of life (HRQoL) domains (physical, social and psychological). The LCQ is calculated as a mean score for each domain ranging from 1 to 7, with a total score ranging from 3 to 21. Higher scores indicate better HRQoL. A clinically meaningful improvement from baseline in HRQoL was defined as ≥1.3-point increase in the LCQ total score at Week 24. The percentage of participants (logistic regression model-based) with a ≥1.3-point increase in the LCQ total score at Week 24 is presented.</description>
          <population>All randomized participants who had taken at least 1 dose of study intervention, had available LCQ data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="404"/>
                <count group_id="O3" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1"/>
                    <measurement group_id="O2" value="75.9"/>
                    <measurement group_id="O3" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.077</p_value>
            <p_value_desc>Comparison based on logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline LCQ total score, and the interaction of baseline LCQ total score by visit as covariates.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>Comparison based on logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline LCQ total score, and the interaction of baseline LCQ total score by visit as covariates.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24</title>
        <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A clinically meaningful improvement from baseline is defined as a ≤-30% change (≥30% reduction) in 24-hour coughs per hour at week 24. The percentage of participants (logistic regression model-based) with a ≤ -30% change from baseline in 24-hour coughs per hour at Week 24 (≥30% reduction from baseline) is presented.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who took at least 1 dose of study intervention, had available 24-hour cough data at baseline and at least one available post-baseline measurement in the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg BID</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≤-30% Change From Baseline in 24-hour Coughs Per Hour at Week 24</title>
          <description>24-hour coughs per hour was defined as the average hourly cough frequency based on 24-hour sound recordings using a digital recording device (cough monitor). A clinically meaningful improvement from baseline is defined as a ≤-30% change (≥30% reduction) in 24-hour coughs per hour at week 24. The percentage of participants (logistic regression model-based) with a ≤ -30% change from baseline in 24-hour coughs per hour at Week 24 (≥30% reduction from baseline) is presented.</description>
          <population>All randomized participants who took at least 1 dose of study intervention, had available 24-hour cough data at baseline and at least one available post-baseline measurement in the treatment period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="67.4"/>
                    <measurement group_id="O3" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.872</p_value>
            <p_value_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline 24-hour coughs per hour and the interaction of baseline 24-hour coughs per hour as covariates.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline 24-hour coughs per hour and the interaction of baseline 24-hour coughs per hour as covariates.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≤-1.3 Point Change From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24</title>
        <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-1.3 point change from baseline in CSD at Week 24 (or ≥1.3 point reduction from baseline) is reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had taken at least 1 dose of study intervention, had available CSD data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≤-1.3 Point Change From Baseline of Mean Weekly Cough Severity Diary (CSD) Total Score at Week 24</title>
          <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-1.3 point change from baseline in CSD at Week 24 (or ≥1.3 point reduction from baseline) is reported.</description>
          <population>All randomized participants who had taken at least 1 dose of study intervention, had available CSD data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                    <measurement group_id="O2" value="74.8"/>
                    <measurement group_id="O3" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly CSD total score, and the interaction of baseline mean weekly CSD total score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly CSD total score, and the interaction of baseline mean weekly CSD total score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≤-2.7 Point Change From Baseline of Mean Weekly CSD Total Score at Week 24</title>
        <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-2.7 point change from baseline in CSD at Week 24 (or ≥2.7 point reduction from baseline) is reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had taken at least 1 dose of study intervention, had available CSD data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≤-2.7 Point Change From Baseline of Mean Weekly CSD Total Score at Week 24</title>
          <description>The 7-item CSD was used to record participants' daily cough frequency, cough intensity, and disruption due to cough. Each item was rated on an 11-point scale ranging from 0 (best) to 10 (worst); the total daily CSD score was the sum of these seven item scores (Min=0, Max=70). Mean weekly CSD total score was defined as the average of the mean total daily scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-2.7 point change from baseline in CSD at Week 24 (or ≥2.7 point reduction from baseline) is reported.</description>
          <population>All randomized participants who had taken at least 1 dose of study intervention, had available CSD data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="46.6"/>
                    <measurement group_id="O3" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly CSD total score, and the interaction of baseline mean weekly CSD total score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly CSD total score, and the interaction of baseline mean weekly CSD total score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≤-30 Millimeter (mm) Change From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24</title>
        <description>The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 (&quot;No Cough&quot;) to 100 (&quot;Extremely Severe Cough&quot;). Mean weekly VAS score was defined as the average of the VAS scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-30 mm change from baseline in cough severity VAS score at Week 24 is reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All randomized participants who had taken at least 1 dose of study intervention, had available VAS data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O2">
            <title>Gefapixant 15 mg BID</title>
            <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
          <group group_id="O3">
            <title>Gefapixant 45 mg</title>
            <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≤-30 Millimeter (mm) Change From Baseline in Cough Severity Visual Analog Scale (VAS) Score at Week 24</title>
          <description>The VAS is a single-item questionnaire with the response on a 100- point scale ranging from 0 (&quot;No Cough&quot;) to 100 (&quot;Extremely Severe Cough&quot;). Mean weekly VAS score was defined as the average of the VAS scores collected during the week prior to each visit. The percentage of participants (logistic regression model-based) with a ≤-30 mm change from baseline in cough severity VAS score at Week 24 is reported.</description>
          <population>All randomized participants who had taken at least 1 dose of study intervention, had available VAS data at baseline, and at least one available post-baseline measurement in the treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="51.4"/>
                    <measurement group_id="O3" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly VAS score, and the interaction of baseline mean weekly VAS score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison based on a logistic regression model that included treatment, visit, treatment-by-visit interaction, gender, region, baseline mean weekly VAS score, and the interaction of baseline mean weekly VAS score by visit as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-Treatment Period: Up to Week 54; Off-Treatment (Off-Tx) Period: From Week 52 through Week 64 (approximately 12 weeks)</time_frame>
      <desc>All-cause mortality (ACM) includes all randomized participants; serious and other AEs include all randomized participants who took ≥1 one dose of study drug. In the treatment period, 3 participants randomized to placebo who took ≥1 incorrect dose(s) of study drug were counted as follows: 2 participants were analyzed in the gefapixant 15 mg arm and 1 in the gefapixant 45 mg arm. AEs and ACM were reported separately for the Treatment Period (MedDRA 23.0) and Off-Tx Period (MedDRA 23.1).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received dose-matched placebo tablets twice daily (BID) during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="E2">
          <title>Gefapixant 15 mg BID</title>
          <description>Participants received a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="E3">
          <title>Gefapixant 45 mg BID</title>
          <description>Participants received a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and 28-week extension period.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Off Tx</title>
          <description>Participants previously treated with dose-matched placebo BID for 52 weeks during the main study and extension study periods were observed for up to 3 months during an optional Off-Treatment Durability study period (participants received no treatment).</description>
        </group>
        <group group_id="E5">
          <title>Gefapixant 15 mg BID: Off Tx</title>
          <description>Participants previously treated with gefapixant 15 mg BID for 52 weeks during the main study and extension study periods were observed for up to 3 months during an optional Off-Treatment Durability study period (participants received no treatment).</description>
        </group>
        <group group_id="E6">
          <title>Gefapixant 45 mg BID: Off Tx</title>
          <description>Participants previously treated with gefapixant BID for 52 weeks during the main study and extension study periods were observed for up to 3 months during an optional Off-Treatment Durability study period (participants received no treatment).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="442"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital choroid plexus cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Disinfectant poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="442"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="290" subjects_at_risk="442"/>
                <counts group_id="E3" subjects_affected="359" subjects_at_risk="440"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="432"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="442"/>
                <counts group_id="E3" events="34" subjects_affected="27" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="432"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="442"/>
                <counts group_id="E3" events="34" subjects_affected="32" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="32" subjects_at_risk="432"/>
                <counts group_id="E2" events="33" subjects_affected="26" subjects_at_risk="442"/>
                <counts group_id="E3" events="57" subjects_affected="47" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="432"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="442"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="440"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="432"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="442"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="101" subjects_affected="70" subjects_at_risk="432"/>
                <counts group_id="E2" events="128" subjects_affected="93" subjects_at_risk="442"/>
                <counts group_id="E3" events="95" subjects_affected="70" subjects_at_risk="440"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="432"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="442"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="440"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="432"/>
                <counts group_id="E2" events="47" subjects_affected="38" subjects_at_risk="442"/>
                <counts group_id="E3" events="39" subjects_affected="30" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="432"/>
                <counts group_id="E2" events="40" subjects_affected="34" subjects_at_risk="442"/>
                <counts group_id="E3" events="26" subjects_affected="19" subjects_at_risk="440"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="432"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="442"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="432"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="442"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="442"/>
                <counts group_id="E3" events="75" subjects_affected="67" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="432"/>
                <counts group_id="E2" events="64" subjects_affected="56" subjects_at_risk="442"/>
                <counts group_id="E3" events="220" subjects_affected="193" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="128" subjects_affected="67" subjects_at_risk="432"/>
                <counts group_id="E2" events="131" subjects_affected="74" subjects_at_risk="442"/>
                <counts group_id="E3" events="131" subjects_affected="70" subjects_at_risk="440"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="442"/>
                <counts group_id="E3" events="60" subjects_affected="60" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="442"/>
                <counts group_id="E3" events="39" subjects_affected="37" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="432"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="442"/>
                <counts group_id="E3" events="29" subjects_affected="19" subjects_at_risk="440"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="432"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="442"/>
                <counts group_id="E3" events="38" subjects_affected="31" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="432"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="442"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="440"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>18006726372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

